home / news / Study team co-investigators updated

Our Monthly Scientific Selection: November Publications on EuroQol Instruments #11

December 10, 2024
[1-30 November 2024] Al Sayah F, Alam A, Short H,...

Four-year EuroQol initiative to help accelerate COVID-19 related research ends

November 5, 2024
Over the duration of the COVID-19 pandemic emergency, the EuroQol...

Our Monthly Scientific Selection: October Publications on EuroQol Instruments #10

November 5, 2024
[1-31 October 2024] Stalmeier PFM, Roudijk B. What Makes the...

Our Monthly Scientific Selection: September Publications on EuroQol Instruments #9

October 14, 2024
[1-30 September 2024] Addo R, Mulhern B, Norman R, Owusu...

EQ-5D-Y-5L launched! A new EuroQol instrument providing children and adolescents with a wider range of options to describe their HRQoL

September 10, 2024
Launched as an approved EuroQol Group instrument today, the EQ-5D-Y-5L...
August 16, 2022

Study team co-investigators updated

The research team for the UK EQ-5D-5L valuation study has been updated. The lead investigator is Donna Rowen (School of Health and Related Research, University of Sheffield) and co-investigators are:

  • Nathan Bray (Centre for Health Economics and Medicines Evaluation, Bangor University)
  • Jill Carlton (School of Health and Related Research, University of Sheffield)
  • Louise Longworth (PHMR, London)
  • David Meads (Academic Unit of Health Economics, Leeds Institute for Health Sciences, University of Leeds)
  • Clara Mukuria (School of Health and Related Research, University of Sheffield)
  • Ciaran O’Neill (Centre for Public Health, Queens University Belfast)
  • Yaling Yang (Nuffield Department of Primary Care Health Sciences, University of Oxford)

This team has been carefully selected by the project’s Steering Group and will bring significant experience and expertise to the valuation study.